Dr. Siegel’s research has almost exclusively focused on multiple myeloma and has been published in many leading medical journals, including Nature, New England Journal of Medicine, Blood and Journal of Clinical Oncology. Dr. Siegel served as the lead investigator of the pivotal multi-center, phase IIb study involving 30 cancer centers in North America that led to the U.S. Food and Drug Administration’s fast-track approval of Kyprolis (carfilzomib) for relapsed multiple myeloma patients. Dr. Siegel is one of 11 investigators nationwide who brought the chemotherapeutic agent Velcade to multiple myeloma patients through his clinical trials with the medication. Velcade is an injectable drug that blocks some of the chemical pathways associated with unregulated cancer cell growth. Dr. Siegel’s studies have shown that Velcade slows and halts the progression of multiple myeloma. He has also been involved in clinical trials for chemotherapeutic agents Revlimid and Carfilzomib.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811